Clinical Trials Directory

Trials / Unknown

UnknownNCT05702996

Multicenter, Uncontrolled Pilot Study Evaluating the Efficacy of Eculizumab in the Treatment of Gemcitabine-induced Thrombotic Microangiopathies

Status
Unknown
Phase
Phase 3
Study type
Interventional
Enrollment
10 (estimated)
Sponsor
University Hospital, Rouen · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The main objective of this prospective multisite trial is to study the evolution of TMA (thrombotic microangiopathy) induced by gemcitabin and treated by eculizumab.

Conditions

Interventions

TypeNameDescription
DRUGEculizumab administrationPatient with Thrombotic microangiopathies induced by gemcitabine will be treat with Eculizumab

Timeline

Start date
2023-03-01
Primary completion
2025-09-01
Completion
2025-09-01
First posted
2023-01-27
Last updated
2023-01-27

Locations

2 sites across 1 country: France

Source: ClinicalTrials.gov record NCT05702996. Inclusion in this directory is not an endorsement.